Abstract
Tumor-targeted delivery of immune stimulatory genes, such as pro-inflammatory cytokines and suicide genes, has shown to cure mouse models of cancer. Total tumor eradication was also found to occur despite subtotal tumor engineering; a phenomenon coined the "bystander effect". The bystander effect in immune competent animals arises mostly from recruitment of a cancer lytic cell-mediated immune response to local and distant tumor cells which escaped gene modification. We have previously described a Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Interleukin 2 (IL2) fusokine (aka GIFT2) which serves as a potent anticancer cytokine and it here served as a means to understand the mechanistic underpinnings to the immune bystander effect in an immune competent model of B16 melanoma. As expected, we observed that GIFT2 secreted by genetically engineered B16 tumor cells induces a bystander effect on non modified B16 cells, when admixed in a 1:1 ratio. However, despite keeping the 1:1 ratio constant, the immune bystander effect was completely lost as the total B16 cell number was increased from 10(4) to 10(6) which correlated with a sharp reduction in the number of tumor-infiltrating NK cells. We found that B16 secrete biol...Continue Reading
References
Dec 1, 1993·The Journal of Clinical Investigation·C L ArteagaJ T Forbes
Oct 1, 1993·Current Opinion in Immunology·D M Pardoll
Jan 1, 1993·Journal of Cellular Biochemistry. Supplement·C L ArteagaJ T Forbes
Apr 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·G DranoffR C Mulligan
Feb 3, 1997·The Journal of Experimental Medicine·H SuzukiT W Mak
Mar 6, 1999·Nature·L UlloaJ Massagué
Apr 13, 1999·Yonsei Medical Journal·C H ChoJ D Kim
Dec 22, 2000·Genes & Development·C PetritschM Oft
Feb 15, 2001·Microscopy Research and Technique·K KoliJ Keski-Oja
May 18, 2001·Nature·S A Rosenberg
Mar 22, 2002·Cancer Control : Journal of the Moffitt Cancer Center·Maria G SotomayorDrew M Pardoll
May 22, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Brad H NelsonTongwen Wang
Jun 10, 2003·Oncogene·Estela E Medrano
Nov 26, 2003·International Immunopharmacology·Susan C McKarnsNorbert E Kaminski
May 29, 2004·FEBS Letters·Graham Pawelec
Dec 18, 2004·Cancer Research·John StaggJacques Galipeau
Oct 18, 2005·Nature Medicine·Marie-Christine MeunierClaude Perreault
Jun 6, 2007·Cancer Immunology, Immunotherapy : CII·Amir KhammariBrigitte Dréno
Citations
Sep 14, 2012·Gene Therapy·L ZhangR A Morgan
Sep 29, 2011·Molecular Cancer·Moutih RafeiJacques Galipeau
Jun 21, 2012·Journal of Translational Medicine·Jon G QuatromoniJames S Economou
Feb 8, 2014·Cell Death & Disease·P ChaudhryE Asselin
Mar 28, 2013·Clinical & Developmental Immunology·Pablo A GonzálezAlexis M Kalergis
Oct 28, 2014·The Journal of Clinical Investigation·Regina LinQi-Jing Li
May 7, 2014·Oncoimmunology·Valérie Janelle, Alain Lamarre
May 10, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Claudia PenafuerteJacques Galipeau
Feb 13, 2018·Oncology Letters·Xiao-Ling FengLing Hu
Jul 9, 2014·The Journal of Immunology : Official Journal of the American Association of Immunologists·Maite AlvarezWilliam J Murphy
Apr 30, 2014·Cancer Immunology Research·Valérie JanelleAlain Lamarre
Nov 19, 2009·Cancer Research·Claudia PenafuerteJacques Galipeau
Dec 17, 2010·Cancer Research·Nancy Díaz-ValdésEsperanza Feijoó
Aug 5, 2016·Cancer Research·Spencer NgJacques Galipeau
Nov 4, 2020·Cancers·Maite AlvarezWilliam J Murphy
Dec 18, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Andrey V MarkovMarina A Zenkova
Apr 4, 2021·Cancers·Hansol LeeJames S Wilmott
Jul 24, 2021·Oncology Reports·Shingo KodamaTetsuro Watabe